Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

2 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
4(50.0%)
Phase 3
2(25.0%)
Phase 2
2(25.0%)
8Total
Phase 1(4)
Phase 3(2)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT06930794Phase 3Recruiting

A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive

Role: lead

NCT06105619Phase 2Active Not Recruiting

A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).

Role: lead

NCT07285148Phase 1Not Yet Recruiting

A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer

Role: lead

NCT05989542Phase 3Recruiting

A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)

Role: lead

NCT04258033Phase 2Active Not Recruiting

A Study of PLB1001 in Non-small Cell Lung Cancer With c-Met Dysregulation(KUNPENG)

Role: lead

NCT03130881Phase 1Unknown

Phase I Study of a Selective ALK Inhibitor PLB1003 in Patients With ALK+ NSCLC.

Role: lead

NCT02978261Phase 1Completed

Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas

Role: lead

NCT02896231Phase 1Completed

First-in-human Phase I Study of a Selective c-Met Inhibitor PLB1001

Role: lead

All 8 trials loaded